Brown J, Dourakis S, Karayiannis P, Goldin R, Chiba J, Ohba H, Miyamura T, Thomas H C
Academic Department of Medicine, St. Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London, United Kingdom.
Hepatology. 1992 Feb;15(2):175-9. doi: 10.1002/hep.1840150202.
The serological responses to two different hepatitis C virus antigens were studied by enzyme-linked immunosorbent assay in a variety of chronic liver diseases and in healthy blood donors. The study population comprised 97 cases of cryptogenic chronic liver disease (40% with a history suggestive of parenterally transmitted non-A, non-B hepatitis and 60% without such a history), 87 cases of other well-characterized chronic liver diseases and 96 voluntary blood donors. The commercially available C100-3 assay and a new assay utilizing a 22 kD recombinant protein (c22) from the nucleocapsid region of the virus were used for antibody detection. Overall in the non-A, non-B hepatitis group, 77% were positive for anti-c22, 55% were positive for anti-C100-3 and 24% were negative by both tests. In the parenterally transmitted chronic liver disease group, 82% were positive for anti-C100-3 and 90% were positive for anti-c22 (not significant). In the cryptogenic chronic liver disease cases 36% were positive for anti-C100-3 and 67% were positive for anti-c22 (p less than 0.001). Only in one case (a patient with hepatitis B virus infection) was anti-C100-3 detected without concomitant anti-c22. None of the voluntary blood donors had detectable hepatitis C virus antibodies. The new enzyme-linked immunosorbent assay test for anti-c22 would appear to be a more sensitive indicator of chronic hepatitis C virus infection than the existing commercial test, suggesting a useful diagnostic role in both cases of cryptogenic chronic non-A, non-B hepatitis liver disease and for the screening of blood products for prevention of hepatitis after transfusion.
通过酶联免疫吸附测定法，研究了多种慢性肝病患者及健康献血者对两种不同丙型肝炎病毒抗原的血清学反应。研究对象包括97例隐源性慢性肝病患者（40%有肠道外传播的非甲非乙型肝炎病史，60%无此类病史）、87例其他特征明确的慢性肝病患者以及96名自愿献血者。采用市售的C100 - 3检测法和一种利用病毒核衣壳区域的22 kD重组蛋白（c22）的新检测法进行抗体检测。总体而言，在非甲非乙型肝炎组中，抗 - c22阳性率为77%，抗 - C100 - 3阳性率为55%，两种检测均为阴性的占24%。在肠道外传播的慢性肝病组中，抗 - C100 - 3阳性率为82%，抗 - c22阳性率为90%（无显著差异）。在隐源性慢性肝病病例中，抗 - C100 - 3阳性率为36%，抗 - c22阳性率为67%（p小于0.001）。仅在1例（1例乙型肝炎病毒感染患者）中检测到抗 - C100 - 3而无伴随的抗 - c22。所有自愿献血者均未检测到丙型肝炎病毒抗体。抗 - c22的新型酶联免疫吸附测定试验似乎比现有的商业检测更能敏感地指示慢性丙型肝炎病毒感染，表明其在隐源性慢性非甲非乙型肝炎肝病病例以及输血后预防肝炎的血液制品筛查中均具有有用的诊断作用。
